Kontrolsüz Diyabetes Mellitus Vakasında Nadir Görülen Amfizematöz Piyelonefrit ile Sistit Birlikteliği: Vaka Raporu ve Literatür derlemesi

Yıl 2019, Cilt: 14 Sayı: 2, 85 - 88, 15.07.2019

Hamit Yıldız

https://doi.org/10.17517/ksutfd.436448

Öz

Amfizematöz
piyelonefrit (EP) ve amfizematöz sistit (EC) bayanlarda daha sık olmak üzere
nadir görülen bir idrar yolları enfeksiyonu tipidir. Hastaların yaklaşık %
90’nında diabetes mellitus (DM) mevcuttur. Kontrolsüz DM’li hastalarda
enfeksiyon sıklığını arttıran faktörler dokularda yüksek glukoz varlığı,
anjiyopati kaynaklı doku perfüzyonunda bozulma ve bozulmuş immün yanıttır.
Genellikle ani başlar ve hızlı seyirlidir. Septisemi ve akut böbrek yetmezliği
semptomlarını takiben kısa sürede ortaya çıkar. Laboratuvar testlerinin kısıtlı
fayda göstermesi nedeniyle kan ve idrar kültürlerinde mikroorganizmaların
üretilmesi kritik önem taşır. Gaz birikimini göstermek, lokalizasyonunu ve
sınırlarını belirlemek  için en sensitif
radyolojik test abdominal bilgisayarlı tomografidir (BT). Güncel hakim genel
görüş kültür sonuçları beklenmeksizin geniş etki spektrumlu antibiyoterapi
başlanmasını takiben hastanın klinik durumuna göre gerekirse perkütan kateter
drenajı yapılmasıdır. Yanıt alınamayan vakalarda nefrektomi yapılır. Bu nedenle
DM tanısı olan ve uygun antibiyoterapiye rağmen yanıtsız idrar yolları
enfeksiyonlarında önplanda EP veya EC düşünülmeli, tanı ve tedavi  için hızlı davranılmalıdır.

Anahtar Kelimeler

Amfizematöz piyelonefrit, amfizematöz sistit, diabetes mellitus

Coexistence of Emphysematous Pyelonephritis and Cystitis Rarely Seen in an Uncontrolled Diabetes Mellitus Case:

Öz

Emphysematous
pyelonephritis (EP) and emphysematous cystitis (EC) are rare urinary tract
infections that are more frequently seen in women. Nearly 90% of the patients
have diabetes mellitus (DM). In uncontrolled DM patients, factors that increase
the frequency of infection consist of presence of high glucose in tissues,
impaired tissue perfusion due to angiopathy and impaired immune response. They
generally start suddenly and progress rapidly. They develop within a short time
following septicemia and acute kidney failure symptoms. Due to the limited
benefit of laboratory tests, growing of microorganisms in blood and urine
cultures is of critical importance. The most sensitive radiological test for
showing gas accumulation as well as identifying its localization and boundaries
is abdominal computed tomography (CT). The current prevailing general opinion
favors starting broad spectrum antibiotherapy without waiting for culture
results and then performing percutaneous catheter drainage if necessary,
depending on the clinical condition of the patient. Nephrectomy is performed in
nonresponsive cases. Therefore, in urinary tract infections that are
nonresponsive despite antibiotherapy in patients diagnosed with DM, EP or EC
should be suspected primarily, and diagnosis and treatment should not be
delayed.

Anahtar Kelimeler

Emphysematous pyelonephritis, emphysematous cystitis, diabetes mellitus

Kaynakça

• 1. Klein FA, Smith MJ, Vick CW, Schneider V. Emphysematous pyelonephritis. S Med J 1986; 79: 41-46.
• 2. Çalışkan Z, Çift A, Vuruşkan H, Kordan Y, Yavaşçaoğlu İ, Oktay B. Amfizematöz pelonefrit: Olgu sunumu. Türk Üroloji Dergisi: 2005; 31: 441-3.
• 3. Atkins RC, Zimmet P. Diabetic kidney disease: Act now or pay later. Saudi J Kidney Dis Transpl. 2010; 21: 217-21.
• 4. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunology Med Microbiol. 1999; 26: 256-65.
• 5. Muller LM, Gorter KJ, Hak E, Goudzward WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005; 41: 281-8.
• 6. Peleg AY, Weeraratha T, McCarthy JS, Davis TM. Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007; 23: 3-13
• 7. Stoeckle M, Kaech C, Trampuz A, Zimmerli W. The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly 2008; 138: 512-9
• 8. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010; 6: 94-101
• 9. Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000; 30: 995-1001
• 10. Price CL, Al Hassi HO, English NR, Blakemore AI, Stagg AJ, Knight SC. Methylglyoxal modulates immune responses: relevance to diabetes. J Cell Mol Med 2010; 14: 1806-15
• 11. Nirmal J, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341: 1906-12
• 12. Vardakas KZ, Siempos II, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med 2007; 24: 1168-71
• 13. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012; 16 Suppl 1: S27-36
• 14. https://www.uptodate.com/contents/susceptibility-to-infections-in-persons-with-diabetes-mellitus?search=SUSCEPTIBILITY%20TO%20INFECTIONS%20IN%20 PERSONS%20 WITH%20DIABETES%20MELLITUS&source=search_result& selected Title=1~150&usage_type=default&display_rank=1 (Access date 22/03/2018).
• 15. Geerlings SE. Urinary tract infections in patients with diabetes mellitus: Epidemiology, pathogenesis and treatment. Int J Antimicrob Agents 2008; 31S: S54-7
• 16. Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol 2009; 182: S51-6
• 17. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 2000; 160: 797-805
• 18. Chen MT, Huang CN, Chou YH, Huang CH, Chiang CP, Liu GC. Percutaneous drainage in the treatment of emphysematous pyelonephritis: 10-year experience. J Urol 1997; 157: 1569
• 19. Evanoff GV, Thompson CS, Foley R, Weinman EJ. Spectrum of gas within the kidney. Emphysematous pyelonephritis and emphysematous pyelitis. Am J Med 1987; 83: 149
• 20. Pontin AR, Barnes RD, Joffe J, Kahn D. Emphysematous pyelonephritis in diabetic patients. Br J Urol 1995; 75: 71
• 21. Shokeir AA, El-Azab M, Mohsen T, El-Diasty T. Emphysematous pyelonephritis: a 15-year experience with 20 cases. Urology 1997; 49: 343
• 22. Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: a review of 135 cases. BJU Int 2007; 100: 17-20
• 23. Kelly HA, MacCallum WG. Pneumaturia. JAMA 1898; 31:375-81.
• 24. Baena JF, Romeu JP, Llopis JA, Tamayo AL, Encinas JJ. Emphysematous cystitis. Case report and review of literature. Actas Urol Esp 2008; 32: 948-50
• 25. Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am 2001; 15: 407-20.
• 26. Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine 2007; 86: 47-53
• 27. Park BS, Lee SJ, Kim YW, Huh JS, Kim JI, Chang SG. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol 2006; 40: 332-8.
• 28. Roy C, Pfleger DD, Tuchmann CM, Lang HH, Saussine CC, Jacqmin D. Emphysematous pyelitis: findings in five patients. Radiology 2001; 218: 647-50.
• 29. Mydlo JH, Maybee GJ, Ali-Khan MM. Percutaneous drainage and/or nephrectomy in the treatment of emphysematous pyelonephritis. Urol Int 2003; 70: 147-50.
• 30. Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N'Dow J. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol 2008; 179: 1844-9.